Literature DB >> 23070254

Palliative care: Aprepitant and control of emesis induced by 5-day chemotherapy.

Richard J Gralla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23070254     DOI： 10.1038/nrclinonc.2012.183

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

Authors:  Lawrence H Einhorn; Mary J Brames; Robert Dreicer; Craig R Nichols; Michael T Cullen; Joseph Bubalo
Journal:  Support Care Cancer       Date:  2007-04-14       Impact factor: 3.603

2.  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

Authors:  Steven Grunberg; Daniel Chua; Anish Maru; José Dinis; Suzanne DeVandry; Judith A Boice; James S Hardwick; Elizabeth Beckford; Arlene Taylor; Alexandra Carides; Fausto Roila; Jørn Herrstedt
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

3.  Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.

Authors:  F D Tattersall; W Rycroft; B Francis; D Pearce; K Merchant; A M MacLeod; T Ladduwahetty; L Keown; C Swain; R Baker; M Cascieri; E Ber; J Metzger; D E MacIntyre; R G Hill; R J Hargreaves
Journal:  Neuropharmacology       Date:  1996       Impact factor: 5.250

4.  Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

Authors:  M Aapro; A Fabi; F Nolè; M Medici; G Steger; C Bachmann; S Roncoroni; F Roila
Journal:  Ann Oncol       Date:  2010-01-15       Impact factor: 32.976

5.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

Authors:  R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro
Journal:  Ann Oncol       Date:  2003-10       Impact factor: 32.976

6.  Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.

Authors: 
Journal:  N Engl J Med       Date:  1995-01-05       Impact factor: 91.245

7.  Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.

Authors:  Costantine Albany; Mary J Brames; Christopher Fausel; Cynthia S Johnson; Joel Picus; Lawrence H Einhorn
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

8.  Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.

Authors:  Mitsue Saito; Kenjiro Aogi; Ikuo Sekine; Hirohisa Yoshizawa; Yasuhiro Yanagita; Hiroshi Sakai; Kenichi Inoue; Chiyoe Kitagawa; Takashi Ogura; Shoichi Mitsuhashi
Journal:  Lancet Oncol       Date:  2009-01-08       Impact factor: 41.316

9.  Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

Authors:  R M Navari; R R Reinhardt; R J Gralla; M G Kris; P J Hesketh; A Khojasteh; H Kindler; T H Grote; K Pendergrass; S M Grunberg; A D Carides; B J Gertz
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.